Trials & R&D · first seen 7h ago, updated 7h ago

DME red flag in Merck Brunello phase III? Surrozen finishes rich

1 outlet Merck & Co. (MSD)

Merck & Co. Inc.’s positive top-line data from the pivotal phase IIb/III Brunello trial with remigromig in adults with diabetic macular edema (DME) came with a possible safety downside, but backers of competitor Surrozen Inc. proved happy a…

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

BioWorld Articles 7h ago
DME red flag in Merck Brunello phase III? Surrozen finishes rich